Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances is a research paper published in Journal for ImmunoTherapy of Cancer (2020). On theSindex it has a DataRank of 0.828. It has been cited 248 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.828
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: ZIA BC 010425
National Cancer Institute
Grant: ZIA BC 010944
National Institutes of Health
Grant: 1Z01BC010425-01
DEVELOPMENT OF VACCINES &VACCINE STRATEGIES FOR CANCER
FWCI
12.80
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Additional file 1 of The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Additional file 1 of The PD-L1 metabolic interactome intersects with choline metabolism and inflammation
Additional file 1 of The PD-L1 metabolic interactome intersects with choline metabolism and inflammation
Additional file 1 of Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
Additional file 1 of Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment